Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.
about
New paradigms in GPCR drug discovery.Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsMetabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.Overview of Critical Parameters for the Design and Execution of a High-Throughput Screen for Allosteric Ligands.Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia.Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild TypeFurther optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compoundAcyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators.Development of 1H-Pyrazolo[3,4-b]pyridines as Metabotropic Glutamate Receptor 5 Positive Allosteric Modulators.Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu3 NAMs.Role of mGlu5 Receptors and Inhibitory Neurotransmission in M1 Dependent Muscarinic LTD in the Prefrontal Cortex: Implications in Schizophrenia.Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.Schizophrenia: synthetic strategies and recent advances in drug design
P2860
Q37140411-19C5ACB6-EA11-4C36-9DAC-827D7E6D6F06Q37183072-D1053F5A-7CD2-42A7-A5BB-3B90291E666AQ38690069-7974828B-10F0-4DA1-9C2A-25E4DEF231F7Q38956226-F2C58FA1-85C9-4592-8B0C-76135BEC40D5Q38966204-A46CF867-5A62-4347-9CD0-876998401080Q39284158-F33F1790-079A-4EF6-AE1D-61DD0B341B98Q40291116-776F5AE9-FEF1-42A3-BCA9-99875DF00D11Q40435465-311EB829-D7ED-43B5-AC8C-7D726069E2D3Q41870911-36FEA185-2C85-4A1F-9F39-52FCD0344041Q41933933-B3CE34E1-CAC8-40F4-8B32-7F202293B6F7Q45793215-3CAD3F21-F933-4B0B-87A1-989F2D4D8B7AQ46417915-A739EDF1-4ED7-460D-9465-D31D5F4BD93EQ47758516-1845D6AE-FDAE-4AD4-98FF-CD9A81475E16Q47836225-06458AA5-4CB7-47BC-A275-8BC30FC035B1Q47865915-E3B365C1-EA09-4F83-A788-00691CD95699Q57393544-BBD29F95-00D4-43D6-972B-2586FBE5C5C1
P2860
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Discovery of VU0409551/JNJ-467 ...... idate Targeting Schizophrenia.
@en
type
label
Discovery of VU0409551/JNJ-467 ...... idate Targeting Schizophrenia.
@en
prefLabel
Discovery of VU0409551/JNJ-467 ...... idate Targeting Schizophrenia.
@en
P2093
P2860
P50
P1476
Discovery of VU0409551/JNJ-467 ...... idate Targeting Schizophrenia.
@en
P2093
Abdellah Ahnaou
Anton Megens
Carlos M Martínez-Viturro
Carrie K Jones
Claire Mackie
Gregor J Macdonald
Hilde Lavreysen
J Scott Daniels
Jerri M Rook
Jesús Alcázar
P2860
P304
P356
10.1021/ACSMEDCHEMLETT.5B00181
P577
2015-05-20T00:00:00Z